The pharmacokinetic profile of fesoterodine: Similarities and differences to tolterodine

Swiss Medical Weekly

Volumn 139, Issue 9-10, 2009, Pages 146-151

  Simona, Hans Uwe ^a   Malhotrab, Bimal ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b PFIZER INC   (United States)

Author keywords

5 hydroxymethyl tolterodine; Drug interactions; Fesoterodine; Muscarinic antagonists; Pharmacokinetics; Tolterodine

Indexed keywords

CYTOCHROME P450 2D6; FESOTERODINE; TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FOOD DRUG INTERACTION; GENETIC ASSOCIATION; HUMAN; HUMAN EXPERIMENT; KIDNEY TUBULE EXCRETION; LIPID DIET; MALE; MEAL; NORMAL HUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; URINALYSIS; ADOLESCENT; ADULT; BLOOD; COMPARATIVE STUDY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVERACTIVE BLADDER; REFERENCE VALUE; URINE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CHROMATOGRAPHY, LIQUID; CRESOLS; CROSS-OVER STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; REFERENCE VALUES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 63849331068     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;48:565-578
2. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 2006;161:1809-1812
3. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420-429
4. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000;85:659-664
5. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919-1924
6. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urol. 2001;57:414-421
7. Nilvebrant L, Hallen B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 1997;60:1129-1136
8. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future. 2004;29:715-720
9. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed, Marcel Dekker Inc., New York.
10. Chapple C, van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52:1204-1212
11. Nitti V, Dmochowski R, Sand P, et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol. 2007;178:2488-2494
12. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urol. 2008;71:839-843
13. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects, and functional diversity. Pharmacogenomics J. 2005;5:6-13.
14. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001;40:227-235
15. Sachse R, Cawello W, Haag MC, et al. Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine. Naunyn-Schmied Arch Pharmacol. 2003;367:R115.
16. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer. 2001;9:442-451
17. 17 Yamreudeewong W, DeBisschop M, Martin LG, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26:421-438 (Pubitemid 36560714)
18. Kastelova A, Yanev S. Propranolol as an inhibitor of some cytochrome P450-dependent monooxygenase activities in native and induced rat liver microsomes. Methods Find Exp Clin Pharmacol. 2002;24:189-194
19. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227